We are the only company today developing a novel G-protein biased signaling dopamine D3 receptor agonist as a potential breakthrough treatment for Parkinson’s Disease (PD) patients suffering from motor symptoms and Levodopa (L-dopa) induced dyskinesia.
The gold standard for treating the symptoms of PD is levodopa (L-dopa); however, within 3 to 5 years of treatment, approximately 50% of patients develop tolerance that necessitates higher doses taken more frequently and experience L-dopa induced dyskinesia (LID), which manifests as abnormal involuntary body motions that can interfere with the patient’s daily life.
PolyCore’s lead compound, PCT-3012, is a novel small molecule drug which has a significantly differentiated mechanism of action designed to modify how L-dopa works, rather than negating its effects, to improve motor symptoms without the development of tolerance, dyskinesia or impulsive behaviors.
See the minds behind PolyCore’s scientific innovation and therapeutic progress.
How can PCT-3012’s differentiated mechanism of action address other CNS disorders?